IHM
EPZM

Iguana Healthcare Management’s Epizyme, Inc EPZM Stock Holding History

Iguana Healthcare Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-30,000
Closed -$683K – 89
2014
Q1 		$683K Buy
+30,000
New +$909K 0.32% 65

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Iguana Healthcare Management's EPZM Position: Q3 2017 in Review

Iguana Healthcare Management sold out of Epizyme, Inc (EPZM) in Q3 2017, closing a stake of 75,000 shares — an estimated $1.13M sold.

Iguana Healthcare Management first reported a position in EPZM in Q2 2015 and held it in 6 quarters. The position peaked at $2.05M in Q2 2016. 104 funds tracked by Wall St. Rank hold EPZM as of Q3 2017.

  • Iguana Healthcare Management reported no remaining Epizyme, Inc position as of Q3 2017 after selling out during the quarter.
  • Iguana Healthcare Management sold 75,000 Epizyme, Inc shares in Q3 2017, an estimated $1.13M.
  • Iguana Healthcare Management first reported a position in Epizyme, Inc in Q2 2015 and held it in 6 quarters.
  • Iguana Healthcare Management's Epizyme, Inc position peaked at $2.05M in Q2 2016.
  • 104 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2017.

Based on Iguana Healthcare Management's 13F filing for Q3 2017, filed 14 Nov 2017.